
PEACCEL at glance
September 23rd, 2023

Making the world
disease free

We find the real drug
lead candidate by
capturing the synergistic effect of
mutations (epistasis)

We have developed the
innov’SAR AI platform
for our partners.
The innov’SAR core approach is interpolative, extrapolative and predicts out-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 Billion mutants per day.
PEACCEL is definitely the only company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of “hit rate”.
PEACCEL's world-class
Data Scientists in Life Sciences
History
2021
Patent on proprietary molecules
Awards Winner in Artificial Intelligence for Life Sciences
2019
Second technology patent by EPO
Contracts with key players in chemical industry
Graphmut launch
innov'SAR platform assembled for Protein Engineering for Drugs - Fixed Drugs Combinations (FDCs)
2018
€2m competitive EU funds
AutomISAR launch
First contracts with key pharmaceuticals companies
2017
innov’SAR core launch
First technology patent delivered by EPO
Presence in Boston, MA, USA
Contract with FDA (USA)
Acquisition of a supercomputer : screening capacity >1Billion mutants/day
2016
€1m seed money
Paris office, France

Artificial Intelligence, Machine Learning, Deep Learning, Biotechnology, Pharmaceuticals, Chemistry
PEACCEL is built around the 6 pillars - P6 - :
Platform | Publications | Patents | Partnership | Products | People










The company operates in Paris (France) and Cambridge (MA, USA).